AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04803435 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine Consultation
Description: Brief telemedicine consultation, blindedto subsequent face-to-face evaluation.
Study NCT04803435 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face Consultation
Description: Direct face-to-face evaluation (without telemedicine consultation before).
Study NCT04717583 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) treatment
Description: After randomization, one side of the face will be treated with IPL using the M22™ Universal IPL device, once every 4 weeks for 3 consecutive times.~Starting from Week 12 (the time point of the primary endpoint), the control side of face will also be treated by IPL if the IPL-treated side shows satisfactory improvement of erythema or telangiectasia by IPL treatment. If the patient was unsatisfied with the improvement in the IPL-treated side at Week 12 visit, no IPL treatment will be given to either side of the face any more.
Study NCT06516731 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pH Balanced Cleanser
Description: Participants will use the pH Balanced Cleanser daily during showers. The cleanser should be applied to the vulva with clean hands, gently worked into a lather, and rinsed clean. Participants will complete baseline and weekly questionnaires and vaginal pH tests over an 8-week period to evaluate the effects on vulvar and vaginal health, including odor and pH levels, and assess the tolerability of the product.
Study NCT06243159 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: JY231
Description: Infusion of JY231 Injection by dose of 1-10×10\^6 TU/kg、 1-5×10\^7 TU/kg、5-10 ×10\^7 TU/kg Administration method: intravenous infusion、Splenic artery infusion、Lymph node infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion (PI evaluation is required)
Study NCT05364489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with Oxaliplatin and TAS-102
Description: Bevacizumab (Anda, Qilu Pharmaceutical): 5 mg/kg, repeated every 2 weeks, administered by intravenous drip (ivgtt).~Oxaliplatin: 85 mg/m2, repeated every 2 weeks, by intravenous infusion (ivgtt). TAS-102: 35 mg/m2 (maximum single dose 80 mg), orally, twice a day, on days 1 to 5, repeated every 2 weeks.~Continuous administration until disease progression, death, toxicity intolerance, withdrawal of informed consent, or other reasons specified in the protocol; for patients who still benefit after comprehensive evaluation after initial disease progression, the investigator may decide whether to continue the treatment with the experimental drug .
Study NCT05721261 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporary Peripheral Nerve Stimulation System
Description: Single use medical device. Therapy consists of single, 1 hour dose of electrical stimulation delivered proximal to injury site.
Study NCT05721261 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Temporary Peripheral Nerve Stimulation System
Description: Single use medical device. Sham treatment consists of single, 1 hour dose of sham stimulation.
Study NCT04267237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1680 mg will be administered by intravenous (IV) infusion on Day 1 of Cycles 1-12.
Study NCT04267237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7198457
Description: RO7198457 will be administered by IV infusion at protocol-defined intervals for 12 cycles.
Study NCT06476080 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided erector spine block
Description: Ultrasound guided thoracic erector spinae block
Study NCT06476080 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior block
Description: Ultrasound guided serratus anterior block
Study NCT06465290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamed-based active movement training with wearable ankle robot
Description: Active movement training through movement games with robotic assistance
Study NCT03899597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: The intervention group (ARTCON) will receive the standard assignment for the elective caesarean section, but at least one hour before surgery oxytocin exposure will be performed with cardiotocographic (CTG) monitoring and obstetrical supervision.
Study NCT03899597 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The control group (SA) will receive the standard assignment for the elective caesarean section, but at least one hour before surgery placebo exposure will be performed with cardiotocographic (CTG) monitoring and obstetrical supervision.
Study NCT06465290 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Passive movement with limited wearable ankle robot
Description: Passive movement in the joint middle range of motion
Study NCT06465290 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active movement training with limited wearable ankle robot
Description: Active movement training without robotic assistance
Study NCT06465290 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ankle torque and motion measurement with limited wearable ankle robot
Description: Ankle torque and motion measurement with no real-time feedback
Study NCT06719375 — intervention group
Intervention type: DEVICE
Intervention: Gait Analysis Using IMU Sensor
Description: Inertial Measurement Unit (IMU) sensor-based 3D gait analysis to assess spasticity and gait impairment. This intervention aims to provide quantitative data on gait parameters in DCM patients before and after surgery.
Study NCT06716424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iGlarLixi (insulin glargine/lixisenatide)
Description: iGlarLixi is available as a sterile solution for injection that will be administered to study participants subcutaneously
Study NCT04743895 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stainless Steel Wire Cerclage
Description: Wire cerclage used to close sternum after cardiothoracic surgery.
Study NCT05018819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study NCT05655572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation Theraoy
Description: After initial baseline assessment patients allocated in AOT group will undergo treatment protocol of 6 weeks having 4 stages of duration 1.5 weeks each performed 3 days per week. . Assessment will be perform at baseline after 2, 4 and 6 weeks
Study NCT05655572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Training
Description: after baseline assessment participants including in this group will perform the tasks for 6 weeks (3 days per week) s and after that again assessment will be made for examining the improvements.Assessment will be perform at baseline after 2 ,4 and 6 weeks
Study NCT05811975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSX01-TCRT injection
Description: individualization TCR-T cell injection
Study NCT04996498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: intrauterine Instillation of oxytocin in distention media used during Hysteroscopic Myomectomy
Study NCT04996498 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sterile bacteriostatic water ampule
Description: a placebo drug similar in shape to oxytocin ampules
Study NCT05643144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: CGM education and glucose data collection for 14 days with a device. Interviews with dyads to assess experience and awareness of hypoglycemic events.
Study NCT05001542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational moral injury video
Description: Educational video that addresses the identification of moral injury and distress in frontline healthcare workers during COVID-19; offers available interventions at the levels of individual, team and organization
Study NCT06030622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and C3 (Metformin, Simvastatin, and Digoxin)
Description: Combination treatment of Metformin, Simvastatin and Digoxin with Gemcitabine (Arm 1)
Study NCT06030622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C3 (Metformin, Simvastatin, and Digoxin) only
Description: C3 only (Metformin, Simvastatin, and Digoxin) if patients decline Gemcitabine (Arm 2).
Study NCT04868045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thyrotropin Releasing Hormone (TRH)
Description: TRH administration will be given as a 200-mcg single IV bolus on Day 1 and Day 5.
Study NCT04868045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levothyroxine
Description: Patients maintenance dose of levothyroxine will be taken throughout the study. On Day~1 and Day 5, the levothyroxine will be taken after the TRH test is complete. On Days 2- 4, the levothyroxine will be taken in the morning.
Study NCT04868045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothyroidism QOL questionnaire
Description: Administer standardized Hypothyroidism QOL questionnaire.
Study NCT04461964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Machine-vision Image Guided Surgery (MvIGS) spine navigation system.
Description: The intended use of the MvIGS navigation system is to provide high quality intraoperative imaging with no radiation exposure. Use of the proprietary integrated surgical light with embedded tracking technology and Flash™ registration allows for continuous and direct visualization of the surgical field. The MvIGS system is exempt from IDE regulations as the device cleared Premarket Notification FDA-510(k) (K162375). The device includes:~* A single mobile cart with a boom arm and an integrated surgical light with embedded tracking technology (P/N 10-0001);~* Proprietary imaging software (P/N 60-0007); and,~* Kit of tacked surgical instruments including a spine reference clamp, awl tip, pedicle probe (P/N 11-0006).
Study NCT04965935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG Oral Tablet
Description: Dapagliflozin will be administered in a dose of 10 mg/day for 12 weeks.
Study NCT04965935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Matching Dapagliflozin Oral Tablet
Description: Placebo will be administered for 12 weeks.
Study NCT05001412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab; apatinib; carboplatin; etoposide
Description: 2 cycle chemotherapy (carboplatin and etoposide), and then 2 cycle chemotherapy (carboplatin and etoposide) combine with Camrelizumab and apatinib, finally maintenance therapy with Camrelizumab and apatinib
Study NCT05978362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Latarjet technique
Description: Realization of a stop according to Latarjet
Study NCT05978362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Latarjet technique
Description: Realization of a stop according to Latarjet
Study NCT05396118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Injection of 4 MBq/kg of 18F-FDG followed by dynamic positron emission tomography (PET) imaging
Study NCT05396118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of hyperpolarized [1-13C]Pyruvate
Description: Injection of one bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized \[1-13C\]Pyruvate followed by magnetic resonance spectroscopy (MRS) / magnetic resonance spectroscopy imaging (MRSI). After a 5-30 min pause, injection of a second bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized \[1-13C\]Pyruvate followed by MRS / MRSI.
Study NCT05396118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/MR/MRS/MRSI scanning
Description: Regional dynamic PET acquisition for up to 90 minutes following 18F-FDG injection is performed focused on a region-of-interest (ROI). Anatomical magnetic resonance imaging (MRI) is performed in the ROI, including diffusion weighted imaging (DWI) and contrast enhanced imaging (DCE). MRS/MRSI is performed following the injections of hyperpolarized \[1-13C\]Pyruvate.
Study NCT05108636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch
Description: Therapeutic touch; It is a low-cost, non-contra-indications, easy-to-apply and non-invasive form of complementary therapy that can be applied anywhere and at any time (Vanaki et al., 2016). Therapeutic touch was developed by Krieger in 1975 as a nursing intervention to help and even heal the patient by balancing the patient's energy field (Marta et al., 2010). The basic assumption of therapeutic touch is that people have energy fields and these energy fields interact with the environment (Hanley, 2008). Therapeutic touch aims to harmonize, renew and heal the flow of the human energy field by removing the blockages of a person's biofield (Mueller et al., 2019). Unlike other touch-based methods such as massage therapy, therapeutic touch does not require the practitioner to physically touch the patient. Instead, the practitioner uses their hands to focus their energy and intent to help the recipient (Hanley, 2008).
Study NCT05108636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Rest
Description: The use of music in the treatment of diseases has been seen in many civilizations since ancient times. In ancient Greek and Roman communities, individuals resorted to music to get rid of their humanitarian problems, while in Ancient Egypt, music was used to give strength to patients during birth (Kor \& Adar, 2016). In today's studies, it has been determined that music positively affects the physiological parameters, nutrition, hospital stay and sleep of the patients (O'Toole et al., 2017; Van Der Heijden et al., 2016). It is important that the sound level is within the appropriate limits while listening to music to the patients. The American Academy of Pediatrics recommends a sound level between 45dB- a maximum of 65dB (ACOG - AAP, 2012). The World Health Organization recommends a sound level of 35 dB during the day and 30 dB at night (Berglund et al., 2000).
Study NCT05401019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: Oral medication, once a day during 16 weeks
Study NCT05401019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Oral medication, once a day during 16 weeks
Study NCT06733038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 840 mg iv over 30 minutes (60 minutes at first infusion) day 1
Study NCT06733038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg iv over 90 minutes at cycle 1 (if well tolerated, it is administered over 60 minutes at cycle 2, and over 30 minutes at cycle 3) day 1
Study NCT06733038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg iv over 90 minutes at cycle 1 (if well tolerated, it is administered over 60 minutes at cycle 2, and over 30 minutes at cycle 3) day 1
Study NCT06733038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan (CPT-11)
Description: 165 mg/sqm iv over 60 minutes day 1
Study NCT06733038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT-11)
Description: 165 mg/sqm iv over 60 minutes day 1
Study NCT06733038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85 mg/sqm iv over 2 hours day 1
Study NCT06733038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/sqm iv over 2 hours day 1
Study NCT06733038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: 200 mg/sqm iv over 2 hours day 1
Study NCT06733038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/sqm iv over 2 hours day 1
Study NCT06733038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil (5-FU)
Description: 3200 mg/sqm 48 h-continuous infusion, starting on day 1
Study NCT06258291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemosystem REBOOT
Description: The HemoSystem REBOOT will selectively remove three mediators largely contributing to sepsis-induced immunosuppression, from extracorporeal circulation based on magnetic beads.
Study NCT06342349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza virus split vaccine (MDCK cells)
Description: Quadrivalent influenza vaccine made from cell matrix (0.5ml/dose).
Study NCT06342349 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent influenza virus split vaccine (Chicken embryo)
Description: Quadrivalent influenza vaccine made from chicken embryo(0.5ml/dose).
Study NCT06342349 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate buffer solution
Description: Phosphate buffer solution without vaccine antigen(0.5ml/dose).
Study NCT06543290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin Pill
Description: Azithromycin 2 grams to be administered prior to start of induction for those randomized to the study arm
Study NCT06543290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin Pill
Description: Azithromycin 2 grams to be administered prior to start of induction for those randomized to the study arm
Study NCT04986969 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online cognitive behavioral therapy
Description: online cognitive behavioral therapy delivered using one of two active methods
Study NCT06733038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)
Description: 3200 mg/sqm 48 h-continuous infusion, starting on day 1
Study NCT06721156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1167
Description: MK-1167 oral capsule
Study NCT06721156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule
Study NCT05347056 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lumbar Spine Magnetic Resonance
Description: Metal artifact reduction sequence (mars), axial t2 sequence
Study NCT05347056 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Isokinetic trunk flexion-extension trunk muscle strength and endurance test
Description: To evaluate for trunk muscle strength and endurance angular velocity of 60 and 120°/s
Study NCT05347056 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lomber Region Range of motion assessment
Description: To evaluate for lomber region ROM with digital inclinometer
Study NCT05347056 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Radiograph
Description: spinal radiograph AP/Lateral
Study NCT05347056 — intervention group
Intervention type: BEHAVIORAL
Intervention: SRS 22
Description: SRS-22 Patient Questionnaire
Study NCT03748563 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ds-MCE and EGD
Description: Procedure of ds-MCE:~The ds-MCE system mainly consists of two parts: the NaviCam magnetically maneuvered capsule endoscopy system and the detachable string part. The capsule, which is partially enclosed within the sleeve, can be actively moved in the esophagus through the control of string. Investigator can examine the entire esophagus several times under real time views. After completing the esophageal examination, the capsule could be detached from the string through injecting air into the hollow string with the syringe. Then, the examination of stomach under magnetic control and small bowel under the natural action of gastrointestinal peristalsis follows.~Procedure of EGD:~The esophagogastroduodenoscopy (EGD) will be performed using conventional upper gastrointestinal video endoscopy, according to the standard procedure at individual centers. EGD will be performed within 48 hours after ds-MCE procedure and usually during the same endoscopic session.
Study NCT05590299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fish oral immunotherapy (codfish)
Description: Codfish in mixture of potato prepared under food manufacturing regulations provided in varying doses
Study NCT05590299 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral immunotherapy
Description: Placebo in potato mixture prepared under food manufacturing regulations provided in varying doses
Study NCT05102838 — intervention group
Intervention type: OTHER
Intervention: Anti-virus treatment
Description: Anti-virus treatment
Study NCT03828708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron in infant formula
Description: Participants will receive the same low-iron (5 mg/L) infant formula. Infants in the standard iron group will add iron supplement to pre-made infant formula so the iron content will be 12 mg/L.
Study NCT04391270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blended intervention
Description: A blended intervention group combining the web-based components with face-to-face workshops and posters
Study NCT04391270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web-based intervention
Description: A web-based intervention only referred to the use of internet without traditional face-to-face workshops and posters
Study NCT04727827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic-guided supportive care
Description: Patients undergoing hematopoietic stem cell transplantation will be genotyped and supportive care therapies tailored to identified drug-gene pairs and guideline recommendations